1. A method for initiating communications with a medical device, the method comprising:
bringing a signal source into contact with a body;
transmitting an oscillatory signal through the body, in which the medical device is implanted, from the signal source to a transducer being coupled to an RF telemetry component of the medical device;
detecting a response of the transducer to the signal; and
activating the RF telemetry component upon detection of the response in order to initiate communications.
2. The method of claim 1, wherein the step of bringing the signal source into contact with the body comprises implanting a device containing the signal source into the body.
3. The method of claim 1, wherein the step of bringing the signal source into contact with the body comprises holding a device containing the signal source against an external surface of the body.
4. The method of claim 1, wherein the step of transmitting is in response to a condition detected by a device containing the signal source.
5. The method of claim 1, wherein the step of transmitting is in response to a predetermined schedule.
6. The method of claim 1, wherein the oscillatory signal is ultrasonic.
7. The method of claim 1, wherein the oscillatory signal is infrared.
8. A medical system, comprising:
at least one implantable device including an RF telemetry component coupled to a signal detector, and a signal transducer coupled to the signal detector, the signal detector controlling activation of the RF telemetry component;
a body-contacting signal source adapted to transmit an oscillatory signal through a body to the transducer of the device, when the device is implanted in the body;
the signal detector, upon detection of a response of the transducer to the signal, activating the RF telemetry component to initiate communications with the implanted device.
9. The medical system of claim 8, wherein the telemetry component is a receiver only.
10. The medical system of claim 8, wherein the telemetry component is a transmitter only.
11. The medical system of claim 8, wherein the telemetry component is a transceiver.
12. The medical system of claim 8, wherein the signal source and the signal transducer are acoustic.
13. The medical system of claim 8, wherein the signal source and the signal transducer are optical.
14. The medical system of claim 8, wherein the signal source is coupled to an implantable sensor, the sensor adapted to control transmission of the signal from the source to the transducer based on a condition sensed by the sensor, when the sensor is implanted in the body.
15. The medical system of claim 14, wherein:
the condition is related to a functional aspect of the body; and
the implanted device is adapted to deliver a therapy according to information received via the communications initiated by the activation of the RF telemetry component by the transducer.
16. The system of claim 14, wherein:
the condition is related to a functional aspect of the sensor; and
the implanted device is adapted to deliver a warning according to information received via the communications initiated by the activation of the RF telemetry component by the transducer.
17. The medical system of claim 8, wherein:
the implantable device is a sensor; and
the signal source is coupled to an implantable therapy delivery device, the therapy delivery device, when implanted, adapted to sense conditions, to control transmission of the signal to the transducer based on the sensed conditions, and to deliver or withhold a therapy according to the sensed conditions in combination with information received from the implanted sensor via the communications initiated by the activation of the RF telemetry component by the transducer.
18. The medical system of claim 8, wherein the signal source is coupled to a body-worn device, including an external interface adapted for controlling the signal source.
19. The medical system of claim 18, wherein the external interface of the body-worn device is further adapted to display messages pertaining to the communications initiated with the implanted device.
20. An implantable medical device, comprising:
a communications module for RF telemetry, the module including a telemetry component being one of a receiver, a transmitter, and a transceiver; and
an acoustic transducer coupled to a detector, the detector coupled to the telemetry component, the detector being adapted to activate the telemetry component upon detection of a response of the transducer to an acoustic activation signal.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A process for modifying an unmodified clay, in particular a montmorillonite type clay, characterized in that the clay is intimately mixed with an organomodifier selected from quaternary ammonium salts, sulphonium salts, phosphonium salts, siliconated ammonium compounds, highly fluorinated ammonium compounds, precursors of said salts and mixtures of at least two of said compounds, in the presence of carbon dioxide (CO2) under pressure.
2. The process according to claim 1, characterized in that the CO2 is in the supercritical state.
3. The process according to claim 1, characterized in that the clay and the organomodifier are intimately mixed before being brought into contact with CO2 under pressure.
4. A The process according to claim 1, characterized in that the quaternary ammonium salt employed is an alkylammonium salt.
5. The process according to claim 4, characterized in that the alkylammonium salt is selected from the group comprising tetraethylammonium chloride, tetrabutylammonium hydrogen sulphate, didodecyldimethylammonium bromide and mixtures thereof.
6. The process according to claim 1, characterized in that the siliconated ammonium compound used is a modified poly(dimethylsiloxane).
7. A The process according to claim 1, characterized in that the highly fluorinated ammonium compound used is tetrahydroperfluorooctyltriethylammonium iodide.
8. The process according to claim 1, characterized in that the quaternary ammonium compound precursors are an amine and an alkyl halide.
9. The process according to claim 1, characterized in that the CO2 is at a pressure of 50 to 300 bars and at a temperature of 40\xb0 C. to 50\xb0 C., advantageously about 40\xb0 C.
10. The biodegradable polyester foam prepared in the presence of an organomodified clay using the process according to claim 1, having a homogeneous, substantially regular, fine and closed cellular structure.
11. Use of a biodegradable polyester foam prepared in the presence of an organomodified clay using the process of claims 1, for the manufacture of exterior coatings, drinks and fast food packaging, bottles, disposable cutlery, thermoformed articles, fibres, films, mixtures with starch, bioresorbable medical implants, agricultural transplantation pots, plant labels and fixings, meditrays, biomaterials and re-absorbable patches.